Another Big Pharma “Cure” for ObesityFriday, November 11, 2011
Another scheme to fight fatness: The Pharmaceutical Daily Journal (WSJ) is touting a new drug “that kills a type of fat cell by choking off its blood supply caused significant weight loss in obese monkeys, potentially setting the stage for a new pharmaceutical approach to attacking obesity.” In other words, a drug that attacks your body and kills off cells. Surely, this drug won’t have any side effects.
Now for the real important information buried in bits and pieces within the article. The study was performed at M.D. Anderson Cancer Center in Houston and rights to the drug have been licensed to Ablaris Therapeutics Inc. The husband and wife research team, Renata Pasqualini and Wadih Arap, have rights to any royalties from the drug, and both of them are investors in Ablaris, as is M.D. Anderson Cancer Center. The study using monkeys was funded by the National Institutes of Health, and the initial study on humans will be funded by M.D. Anderson Cancer Center.
So lemme understand: M.D. Anderson Cancer Center hosts researchers who are performing a cancer study and developing a new drug, and that cancer study churns out an alternative use (anti-obesity) for the drug being studied. So M.D. Anderson then funds a study using obese humans to look at the potential for that alternative use, and then they license the drug to a pharmaceutical company and then invest in that company, as do the researchers who did the study.
Do people really believe that the medical establishment and its enablers wants to cure disease and obesity?